LaVoie Health Science Blog

JANUARY 26, 2021

Panelists, including myself as moderator, consisted of industry leaders, including Dr. Alexandra Goll, Managing Director of Biopharma Advisory; Brad Loncar, CEO of Loncar Investments; and Amit Munshi, President, CEO and Board Member of Arena Pharmaceuticals.

Biopharma 52

Biopharma Life science Biotechnology 52

Frost & Sullivan

JULY 22, 2021

Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D).

Biotech 98

Biotech Biopharmaceuticals Biotechnology Government 98

Frost & Sullivan

AUGUST 29, 2024

However, the pharma/biopharma industry overall shows stagnant R&D activity. Conversely, small-to-mid, and emerging biopharma players, with 1 or 2 molecules in the pipeline, contribute over 16%. As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8%

Biopharma 52

Biopharma Biotechnology Contract research organization Utilities 52

LaVoie Health Science Blog

AUGUST 16, 2022

Plumstead brings over 20 years of experience leading product and corporate public relations initiatives for companies in the pharmaceutical, biotechnology, and medical device sectors. Plumstead brings expertise in commercial strategic communications programming and execution from pharma to biopharma and beyond.

Biopharma 52

Biopharma Biotechnology 52

Frost & Sullivan

APRIL 3, 2024

Simtra BioPharma Solutions announced over $250 million expansion of its sterile fill/finish manufacturing campus in Bloomington, Indiana. FUJIFILM Diosynth Biotechnologies invested $1.6 SCHOTT Pharma announced expansion plans in the US to meet the growing demand for mRNA vaccines, GLP1 drugs, and biologics.

Biopharmaceuticals 59

Biopharmaceuticals Biopharma Biotechnology Life science 59

Frost & Sullivan

APRIL 25, 2023

years, to become a truly global company with a diverse mix of public sector and biopharma clients. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. Christine Dingivan said, “This award recognizes the efforts of everyone who works at Emmes.

Biopharmaceuticals 52

Biopharmaceuticals Biopharma Biotechnology Contract research organization 52

LaVoie Health Science Blog

JULY 16, 2021

Paul Sagan, Vice President of Investor Relations and Corporate Communications, discusses the growing investment case for ESG reporting within the biotechnology field, the unique challenges of developing an ESG approach in the life sciences, and the important considerations posed by potential new SEC recommendations and international ESG standards.

Life science 69

Life science Biopharma Biotech Biotechnology 69

Jake Jorgovan

FEBRUARY 5, 2025

Updated: February 2025 In the intricate world of biotechnology, snagging the perfect talent feels like searching for a rare gene in a vast genome. Enter our curated selection of the Top 12 Biotechnology Recruiters, Headhunters, and Executive Search Firms.

Biotechnology 130

Biotechnology Life science Biotech Biopharma 130

Jake Jorgovan

FEBRUARY 5, 2025

The Value of a Biopharma Consulting Firm Beyond mere compliance, these consultants offer strategic vision. BCG in the Biopharma Industry : BCG excels in biopharma consulting, focusing on digital tools, data, and analytics to enhance R&D and commercial strategies, and operational excellence in drug development.

Biopharmaceuticals 130

Biopharmaceuticals Biopharma Biotech Life science 130

Jake Jorgovan

FEBRUARY 2, 2025

They offer a wealth of expertise in biotechnology, pharmaceuticals, and healthcare, guiding companies through product development, market strategies, and regulatory compliance. The company addresses the challenges faced by pharmaceutical, medical device, biotechnology, and diagnostic firms. What Life Science Consultant Will You Choose?

Life science 130

Life science Biotech Biotechnology Engineering 130

Frost & Sullivan

JANUARY 23, 2025

APAC-Based CDMOs Expanding Capabilities With potential regulatory changes, including the Biosecure Act affecting China-based CDMOs , companies in South Korea and India are positioning themselves to capture growing demand for pharmaceutical clinical and commercial scale manufacturing, in US biopharma.

Biotechnology 52

Biotechnology Mergers and acquisition activities Biotech Biopharma 52